4 results
To evaluate the safety and tolerability of FFP104 in PBC subjects following repeat doses of FFP104
The primary efficacy endpoint is treatment success in the therapy for mild to moderate Crohn*s disease with fisultas defined by: - A reduction of at least 50% in the number of draining fistulas at both week 4 and week 8
To evaluate the safety and efficacy of intravenously administered FFP104 in subjects with active Crohn*s disease following repeat doses of FFP104.
to assess the efficacy of a 16-week treatment period of low dose amitriptyline (10-20 mg nightly) or mirtazapine (7.5 - 15 mg nightly) on subjective sleep quality compared to placebo added to usual care in patients with insomnia disorder with sleep…